Randomized Placebo-Controlled Trial Assessing a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Plasma Asymmetric Dimethylarginine Concentration in Mild to Moderate CKD

P.W.B. Nanayakkara; J.C. Kiefte-de Jong; P.M. ter Wee; C.D.A. Stehouwer; F.J. van Ittersum; M.R. Olthof; T. Teerlink; J. Twisk; C. van Guldener; Y.M. Smulders

doi:https://doi.org/10.1053/j.ajkd.2008.06.016

Randomized Placebo-Controlled Trial Assessing a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Plasma Asymmetric Dimethylarginine Concentration in Mild to Moderate CKD

P.W.B. Nanayakkara, J.C. Kiefte-de Jong, P.M. ter Wee, C.D.A. Stehouwer, F.J. van Ittersum, M.R. Olthof, T. Teerlink, J. Twisk, C. van Guldener, Y.M. Smulders

Research output: Contribution to journal › Article › Academic › peer-review

40 Citations (Scopus)

Abstract

Background: Chronic kidney disease (CKD) is associated with an increased incidence of cardiovascular disease (CVD). The Anti-oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study showed that a multistep treatment strategy improved carotid intima-media thickness, endothelial function, and microalbuminuria in patients with stages 2 to 4 CKD. Increased plasma concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, have been linked to greater CVD risk in patients with CKD. The aim of this study is to assess effects of the multistep intervention on plasma ADMA concentrations in the ATIC Study. Study Design: Secondary analysis of a randomized double-blind placebo-controlled trial. Setting & Participants: 93 patients with creatinine clearance of 15 to 70 mL/min/1.73 m

Original language	English
Pages (from-to)	41-50
Journal	American Journal of Kidney Diseases
Volume	53
Issue number	1
DOIs	https://doi.org/10.1053/j.ajkd.2008.06.016
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1053/j.ajkd.2008.06.016

Cite this

Nanayakkara, P. W. B., Kiefte-de Jong, J. C., ter Wee, P. M., Stehouwer, C. D. A., van Ittersum, F. J., Olthof, M. R., Teerlink, T., Twisk, J., van Guldener, C., & Smulders, Y. M. (2009). Randomized Placebo-Controlled Trial Assessing a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Plasma Asymmetric Dimethylarginine Concentration in Mild to Moderate CKD. American Journal of Kidney Diseases, 53(1), 41-50. https://doi.org/10.1053/j.ajkd.2008.06.016

@article{774fd89de0b84f179c14e0e391861a86,

title = "Randomized Placebo-Controlled Trial Assessing a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Plasma Asymmetric Dimethylarginine Concentration in Mild to Moderate CKD",

abstract = "Background: Chronic kidney disease (CKD) is associated with an increased incidence of cardiovascular disease (CVD). The Anti-oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study showed that a multistep treatment strategy improved carotid intima-media thickness, endothelial function, and microalbuminuria in patients with stages 2 to 4 CKD. Increased plasma concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, have been linked to greater CVD risk in patients with CKD. The aim of this study is to assess effects of the multistep intervention on plasma ADMA concentrations in the ATIC Study. Study Design: Secondary analysis of a randomized double-blind placebo-controlled trial. Setting & Participants: 93 patients with creatinine clearance of 15 to 70 mL/min/1.73 m",

author = "P.W.B. Nanayakkara and {Kiefte-de Jong}, J.C. and {ter Wee}, P.M. and C.D.A. Stehouwer and {van Ittersum}, F.J. and M.R. Olthof and T. Teerlink and J. Twisk and {van Guldener}, C. and Y.M. Smulders",

note = "J AN",

year = "2009",

doi = "https://doi.org/10.1053/j.ajkd.2008.06.016",

language = "English",

volume = "53",

pages = "41--50",

journal = "American Journal of Kidney Diseases",

issn = "0272-6386",

publisher = "W.B. Saunders Ltd",

number = "1",

}

Nanayakkara, PWB, Kiefte-de Jong, JC, ter Wee, PM, Stehouwer, CDA, van Ittersum, FJ, Olthof, MR, Teerlink, T, Twisk, J, van Guldener, C & Smulders, YM 2009, 'Randomized Placebo-Controlled Trial Assessing a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Plasma Asymmetric Dimethylarginine Concentration in Mild to Moderate CKD', American Journal of Kidney Diseases, vol. 53, no. 1, pp. 41-50. https://doi.org/10.1053/j.ajkd.2008.06.016

Randomized Placebo-Controlled Trial Assessing a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Plasma Asymmetric Dimethylarginine Concentration in Mild to Moderate CKD. / Nanayakkara, P.W.B.; Kiefte-de Jong, J.C.; ter Wee, P.M. et al.
In: American Journal of Kidney Diseases, Vol. 53, No. 1, 2009, p. 41-50.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Randomized Placebo-Controlled Trial Assessing a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Plasma Asymmetric Dimethylarginine Concentration in Mild to Moderate CKD

AU - Nanayakkara, P.W.B.

AU - Kiefte-de Jong, J.C.

AU - ter Wee, P.M.

AU - Stehouwer, C.D.A.

AU - van Ittersum, F.J.

AU - Olthof, M.R.

AU - Teerlink, T.

AU - Twisk, J.

AU - van Guldener, C.

AU - Smulders, Y.M.

N1 - J AN

PY - 2009

Y1 - 2009

N2 - Background: Chronic kidney disease (CKD) is associated with an increased incidence of cardiovascular disease (CVD). The Anti-oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study showed that a multistep treatment strategy improved carotid intima-media thickness, endothelial function, and microalbuminuria in patients with stages 2 to 4 CKD. Increased plasma concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, have been linked to greater CVD risk in patients with CKD. The aim of this study is to assess effects of the multistep intervention on plasma ADMA concentrations in the ATIC Study. Study Design: Secondary analysis of a randomized double-blind placebo-controlled trial. Setting & Participants: 93 patients with creatinine clearance of 15 to 70 mL/min/1.73 m

AB - Background: Chronic kidney disease (CKD) is associated with an increased incidence of cardiovascular disease (CVD). The Anti-oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study showed that a multistep treatment strategy improved carotid intima-media thickness, endothelial function, and microalbuminuria in patients with stages 2 to 4 CKD. Increased plasma concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, have been linked to greater CVD risk in patients with CKD. The aim of this study is to assess effects of the multistep intervention on plasma ADMA concentrations in the ATIC Study. Study Design: Secondary analysis of a randomized double-blind placebo-controlled trial. Setting & Participants: 93 patients with creatinine clearance of 15 to 70 mL/min/1.73 m

U2 - https://doi.org/10.1053/j.ajkd.2008.06.016

DO - https://doi.org/10.1053/j.ajkd.2008.06.016

M3 - Article

C2 - 18786751

SN - 0272-6386

VL - 53

SP - 41

EP - 50

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

IS - 1

ER -

Nanayakkara PWB, Kiefte-de Jong JC, ter Wee PM, Stehouwer CDA, van Ittersum FJ, Olthof MR et al. Randomized Placebo-Controlled Trial Assessing a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Plasma Asymmetric Dimethylarginine Concentration in Mild to Moderate CKD. American Journal of Kidney Diseases. 2009;53(1):41-50. doi: https://doi.org/10.1053/j.ajkd.2008.06.016